Chengdu Olymvax Biopharmaceuticals (SH:688319)2024-08-23 07:36Sales Performance - In the first half of 2024, the sales revenue of the core product, adsorbed tetanus vaccine, showed a steady growth of approximately 6.8% year-on-year [2][3] - Sales in the blood product sector experienced a decline, but sales in the disease control sector achieved good growth through enhanced market access and academic promotion [3] Clinical Trials Progress - As of mid-August 2024, approximately 4,100 cases have been enrolled in the Phase III clinical trial of the recombinant Staphylococcus aureus vaccine, with full enrollment expected to be completed in the first half of next year [3] - The clinical trial plan for the vaccine requires the collection of 42 confirmed cases of Staphylococcus aureus infection and completion of vaccinations for all 6,000 subjects before unblinding analysis can occur [3] Product Development - The company submitted a communication application for the AC-Hib combined vaccine to the CDE in April 2024 and is currently preparing relevant materials based on feedback received [3][4] - The company has a multi-layered strategic layout for its pipeline, with significant achievements in bacterial vaccine platforms and ongoing development of viral vaccine platforms [4] Market Strategy - The company currently has no plans to adjust the price of the adsorbed tetanus vaccine, as sales in the disease control sector have shown steady growth [3][4] - The company will closely monitor market changes and may adjust prices if its market share is affected by competitors' price changes [4] Research and Development Focus - The company is conducting research on four "super bacteria" vaccines, which are classified as global Class 1 new drugs, making it one of the most comprehensive vaccine companies in this field in China [4]